Leerink Partnrs Analysts Raise Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Pfizer in a report issued on Wednesday, December 18th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will earn $2.90 per share for the year, up from their prior forecast of $2.82. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer's revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.17) EPS.

A number of other analysts also recently issued reports on the company. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 price objective for the company. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Citigroup initiated coverage on shares of Pfizer in a report on Friday, October 25th. They issued a "neutral" rating and a $30.00 target price for the company. Bank of America reiterated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $32.14.

Pfizer Stock Performance

NYSE PFE traded up $0.35 on Monday, hitting $26.71. 35,265,977 shares of the company's stock traded hands, compared to its average volume of 39,021,137. Pfizer has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market capitalization of $151.37 billion, a PE ratio of 36.10, a P/E/G ratio of 0.63 and a beta of 0.65. The firm's 50-day moving average price is $26.82 and its two-hundred day moving average price is $28.16. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.44%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is currently 232.43%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Birmingham Capital Management Co. Inc. AL increased its stake in shares of Pfizer by 2.7% during the third quarter. Birmingham Capital Management Co. Inc. AL now owns 186,650 shares of the biopharmaceutical company's stock valued at $5,402,000 after acquiring an additional 4,887 shares during the period. Copley Financial Group Inc. acquired a new position in shares of Pfizer during the 3rd quarter valued at $577,000. Logan Capital Management Inc. raised its stake in shares of Pfizer by 2.7% in the 3rd quarter. Logan Capital Management Inc. now owns 580,545 shares of the biopharmaceutical company's stock worth $16,801,000 after buying an additional 15,160 shares in the last quarter. Inspire Trust Co. N.A. lifted its holdings in shares of Pfizer by 19.1% in the third quarter. Inspire Trust Co. N.A. now owns 92,708 shares of the biopharmaceutical company's stock valued at $2,683,000 after buying an additional 14,891 shares during the period. Finally, Peapack Gladstone Financial Corp boosted its stake in Pfizer by 23.9% during the third quarter. Peapack Gladstone Financial Corp now owns 762,976 shares of the biopharmaceutical company's stock valued at $22,082,000 after buying an additional 147,405 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.